Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy. Academic Article

abstract

• Community-acquired bacterial pneumonia (CABP) is a leading cause of death worldwide. However, antibacterial agents used to treat common pathogens in CABP are marked by adverse drug events and increasing antimicrobial resistance. Solithromycin is a new ketolide antibiotic, based on the macrolide antibiotic structure, being studied for use in CABP. It has efficacy in vitro against the common causative pathogens in CABP including Streptococcus pneumoniae, Haemophilus influenzae, and atypical pathogens. In Phase II and Phase III clinical trials, it has been demonstrated efficacious as a single agent for treatment of CABP with an apparently milder adverse event profile than alternative agents.

authors

• Udeani, George

published proceedings

• Drug Des Devel Ther

altmetric score

• 0.5

author list (cited authors)

• Donald, B. J., Surani, S., Deol, H. S., Mbadugha, U. J., & Udeani, G.

citation count

• 20

complete list of authors

• Donald, Bryan J||Surani, Salim||Deol, Harmeet S||Mbadugha, Uche J||Udeani, George

publication date

• January 2017

publisher

• Taylor & Francis  Publisher

keywords

• Anti-Bacterial Agents
• Cabp
• Community-acquired Bacterial Pneumonia
• Community-acquired Infections
• Drug Resistance, Bacterial
• Humans
• Macrolide Antibiotics
• Macrolides
• Microbial Sensitivity Tests
• Molecular Conformation
• Pneumonia, Bacterial
• Solithromycin
• Streptococcus Pneumoniae
• Triazoles

Digital Object Identifier (DOI)

• 10.2147/DDDT.S119545

start page

• 3559

end page

• 3566

volume

• 11

URL

• http://dx.doi.org/10.2147/dddt.s119545